Ivantis Announces Results of Landmark Prospective, Randomized Comparative MIGS Clinical Trial

16 April 2018

International Multi-center Study Compares Effectiveness of the Hydrus® Microstent to Two iStent® Trabecular Micro-Bypass Stents in Standalone Glaucoma WASHINGTON, and IRVINE, Calif., April 16, 2018 /PRNewswire/ — Ivantis Inc., developer of the novel Hydrus® Microstent, a device designed to lower eye pressure for open-angle glaucoma patients, announced today the 12-month results of the COMPARE study for minimally invasive glaucoma surgery […]

Continue Reading

Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy Products

Financing led by GV to focus on lead programs for next-generation oncology cell therapies Proprietary platform enables installation of pharmacologic operating systems in cell and gene therapy products to provide treating physicians with precise and dynamic control of engineered cells in patients December 06, 2017 06:15 AM Eastern Standard Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Obsidian Therapeutics, Inc., […]

Continue Reading

Ivantis Hits 2 Major Milestones for its Minimally Invasive Glaucoma Surgery (MIGS)

08 January 2018

In October, Ivantis completed its pre-market approval for Hydrus Microstent, its Minimally Invasive Glaucoma Surgery procedure. Dave Van Meter, president and CEO of Ivantis, elaborates further on the importance of this milestone: “The submission of Ivantis’ PMA marks a significant milestone toward our goal of bringing the Hydrus Microstent to market in the United States […]

Continue Reading

Palleon Pharmaceuticals Raises $47.6 million to Develop Glycoimmune Checkpoint Inhibitors

04 October 2017

Company will target glycan-sensing checkpoints to enable both innate and adaptive immune responses to cancer WALTHAM, Mass., October 4, 2017 — Palleon Pharmaceuticals, a company focused on developing the first Glycoimmune Checkpoint Inhibitors to treat cancer, today announced the completion of a $47.6 million Series A financing from leading biotech venture investors SR One, Pfizer Ventures, […]

Continue Reading

Bioverativ And Bicycle Therapeutics Enter Into Strategic Research Collaboration To Develop Therapies For Haemophilia And Sickle Cell Disease

06 September 2017

Bicycle to receive an upfront payment of $10 million, with potential for future milestones WALTHAM, Mass. and CAMBRIDGE, U.K., September 6, 2017 – Bioverativ Inc. (NASDAQ: BIVV), a global biotechnology company focused on the discovery, development and commercialisation of innovative therapies for haemophilia and other rare blood disorders, and Bicycle Therapeutics Ltd., a biotechnology company […]

Continue Reading

Earlens closes $118m in mixed debt and equity round

05 June 2017

Earlens said today it closed a total of $118 million in funding, with $73 million coming from an offering of Series C preferred stock and $45 from a structured debt facility with CRG LP. The Earlens device, which won 510(k) clearance from the FDA in October 2015, uses a laser diode attached to a behind-the-ear […]

Continue Reading

Bicycle Therapeutics Closes £40 Million ($52 Million) In Series B Financing To Advance Clinical Pipeline

01 June 2017

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, today announced the successful completion of a £40 million Series B financing round. Proceeds will be used to further the development of multiple drug candidates, including Bicycle’s lead molecule, BT1718, a first-in-class drug for cancers […]

Continue Reading

Moximed Closes Oversubscribed $50MM Financing Round

16 March 2017

Moximed®, Inc., developer of unicompartmental load absorber implants for active patients with painful knee osteoarthritis (OA), announced today an oversubscribed Series C round of $50MM with new investors Advent Life Sciences and Future Fund joining existing investors NEA, Morgenthaler Ventures, Gilde Healthcare, GBS Venture Partners, and Vertex Healthcare. As part of the financing, Shahzad Malik, […]

Continue Reading

Ivantis Raises $25 Million Series C to Fund Future US Commercialization of the Hydrus™ Microstent for Minimally Invasive Glaucoma Surgery (MIGS)

09 January 2017

Ivantis Inc., developer of the novel Hydrus™ Microstent device designed to lower eye pressure for glaucoma patients, announced today that it closed a $25 million Series C financing. The round was led by new investor RA Capital Management, and included new investor Mérieux Développement, as well as existing investors. The funds will extend Ivantis’ runway […]

Continue Reading